May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
September 2023 in “Journal of the American Academy of Dermatology” Oral difelikefalin significantly reduces itch in notalgia paresthetica.
3 citations
,
October 2021 in “Clinical, Cosmetic and Investigational Dermatology” Setipiprant did not significantly improve hair growth in men with hair loss.
March 2019 in “Reactions Weekly”
April 2023 in “Journal of The American Academy of Dermatology” Some drugs linked to growth hormones may increase the chance of hair loss in women.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
June 2026 in “University of Science and Technology Journal for Medical Sciences” PRP gel may be slightly more effective than phenytoin cream for healing diabetic foot ulcers.
December 2024 in “Ukrainian Journal of Dermatology Venerology Cosmetology” "Alpenta" effectively reduces hair loss and improves hair growth in women with telogen effluvium.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
April 2023 in “Journal of Investigative Dermatology” Treprostinil, a drug, can delay wound healing in healthy cells but doesn't affect diabetic foot ulcer cells, suggesting further research could help understand its role in treating these ulcers.
January 2018 in “Springer eBooks” Terbinafine is the most effective medicine for fungal nail infections, especially for diabetics and those with weak immune systems.
9 citations
,
February 2025 in “Journal of Nanobiotechnology” Biomimetic nanovesicles can speed up diabetic wound healing by regulating immune cell behavior and metabolism.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
5 citations
,
September 2015 in “Medical hypotheses” Topical sulfonylurea may reduce excessive hair growth caused by certain medications.
July 2025 in “Journal of the European Academy of Dermatology and Venereology”
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
May 2026 in “Open Access CRIS of the University of Bern” GLP-1 receptor agonists can both help and harm hair, so careful monitoring is needed.
September 2025 in “Cureus” GLP-1 agonists may help treat certain skin conditions.
December 2022 in “Molecular Pharmaceutics” Latanoprost-loaded nanotransfersomes could help treat hair loss by promoting hair growth.
April 2026 in “Meditsinskiy sovet = Medical Council” Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
1 citations
,
February 2025 in “International Journal of Dermatology” Abrocitinib may effectively treat Lichen Planopilaris.
July 2024 in “Journal of Investigative Dermatology” September 2015 in “Photodiagnosis and Photodynamic Therapy” December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
2 citations
,
February 2021 in “Indian Dermatology Online Journal” Imatinib can cause hair loss due to lichen planopilaris.
Baricitinib shows promise for treating alopecia areata with mild side effects.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.